These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 31461189)

  • 1. Towards Identification of Essential Structural Elements of Organoruthenium(II)-Pyrithionato Complexes for Anticancer Activity.
    Kladnik J; Kljun J; Burmeister H; Ott I; Romero-Canelón I; Turel I
    Chemistry; 2019 Nov; 25(62):14169-14182. PubMed ID: 31461189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pyrithione-based ruthenium complexes as inhibitors of aldo-keto reductase 1C enzymes and anticancer agents.
    Kljun J; Anko M; Traven K; Sinreih M; Pavlič R; Peršič Š; Ude Ž; Codina EE; Stojan J; Lanišnik Rižner T; Turel I
    Dalton Trans; 2016 Aug; 45(29):11791-800. PubMed ID: 27357845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring pta Alternatives in the Development of Ruthenium-Arene Anticancer Compounds.
    Kljun J; Rebernik M; Balsa LM; Kladnik J; Rapuš U; Trobec T; Sepčić K; Frangež R; León IE; Turel I
    Molecules; 2023 Mar; 28(6):. PubMed ID: 36985471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interactions of two cytotoxic organoruthenium(II) complexes with G-quadruplex.
    Seršen S; Šket P; Plavec J; Turel I
    J Inorg Biochem; 2016 Jul; 160():70-7. PubMed ID: 26606993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Water-soluble Ru(II)- and Ru(III)-halide-PTA complexes (PTA=1,3,5-triaza-7-phosphaadamantane): Chemical and biological properties.
    Battistin F; Scaletti F; Balducci G; Pillozzi S; Arcangeli A; Messori L; Alessio E
    J Inorg Biochem; 2016 Jul; 160():180-8. PubMed ID: 26920229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-Related Mode-of-Action Differences of Anticancer Organoruthenium Complexes with β-Diketonates.
    Seršen S; Kljun J; Kryeziu K; Panchuk R; Alte B; Körner W; Heffeter P; Berger W; Turel I
    J Med Chem; 2015 May; 58(9):3984-96. PubMed ID: 25856666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ru(ii)-(PTA) and -mPTA complexes with N
    Wołoszyn A; Pettinari C; Pettinari R; Badillo Patzmay GV; Kwiecień A; Lupidi G; Nabissi M; Santoni G; Smoleński P
    Dalton Trans; 2017 Aug; 46(30):10073-10081. PubMed ID: 28731114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural Isomerism and Enhanced Lipophilicity of Pyrithione Ligands of Organoruthenium(II) Complexes Increase Inhibition on AChE and BuChE.
    Kladnik J; Ristovski S; Kljun J; Defant A; Mancini I; Sepčić K; Turel I
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32781544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imine-N-Heterocyclic Carbenes as Versatile Ligands in Ruthenium(II) p-Cymene Anticancer Complexes: A Structure-Activity Relationship Study.
    Yang Y; Guo L; Tian Z; Liu X; Gong Y; Zheng H; Ge X; Liu Z
    Chem Asian J; 2018 Oct; 13(19):2923-2933. PubMed ID: 30101417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA structural distortions induced by ruthenium-arene anticancer compounds.
    Gossens C; Tavernelli I; Rothlisberger U
    J Am Chem Soc; 2008 Aug; 130(33):10921-8. PubMed ID: 18651736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experimental and theoretical investigations of cyclometalated ruthenium(ii) complex containing CCC-pincer and anti-inflammatory drugs as ligands: synthesis, characterization, inhibition of cyclooxygenase and in vitro cytotoxicity activities in various cancer cell lines.
    Tabrizi L; Olasunkanmi LO; Fadare OA
    Dalton Trans; 2019 Jan; 48(2):728-740. PubMed ID: 30560261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitochondrial fragmentation is an important cellular event induced by ruthenium(II) polypyridyl complexes in osteosarcoma cells.
    Du Y; Fu X; Li H; Chen B; Guo Y; Su G; Zhang H; Ning F; Lin Y; Mei W; Chen T
    ChemMedChem; 2014 Apr; 9(4):714-8. PubMed ID: 24403015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of PPh₃ moiety in the anticancer activity of new organometallic ruthenium complexes.
    Sáez R; Lorenzo J; Prieto MJ; Font-Bardia M; Calvet T; Omeñaca N; Vilaseca M; Moreno V
    J Inorg Biochem; 2014 Jul; 136():1-12. PubMed ID: 24690555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical Anticancer Activity of an Electron-Deficient Organoruthenium(II) Complex.
    Soldevila-Barreda JJ; Azmanova M; Pitto-Barry A; Cooper PA; Shnyder SD; Barry NPE
    ChemMedChem; 2020 Jun; 15(11):982-987. PubMed ID: 32237195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and structural characterization of copper(I) complexes bearing N-methyl-1,3,5-triaza-7-phosphaadamantane (mPTA): cytotoxic activity evaluation of a series of water soluble Cu(I) derivatives containing PTA, PTAH and mPTA ligands.
    Porchia M; Benetollo F; Refosco F; Tisato F; Marzano C; Gandin V
    J Inorg Biochem; 2009 Dec; 103(12):1644-51. PubMed ID: 19822369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ruthenium(II) polypyridyl complexes: cellular uptake, cell image and apoptosis of HeLa cancer cells induced by double targets.
    Yu Q; Liu Y; Xu L; Zheng C; Le F; Qin X; Liu Y; Liu J
    Eur J Med Chem; 2014 Jul; 82():82-95. PubMed ID: 24878637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticancer Ru(η
    Arshad J; Hanif M; Movassaghi S; Kubanik M; Waseem A; Söhnel T; Jamieson SMF; Hartinger CG
    J Inorg Biochem; 2017 Dec; 177():395-401. PubMed ID: 28916262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes.
    Scolaro C; Bergamo A; Brescacin L; Delfino R; Cocchietto M; Laurenczy G; Geldbach TJ; Sava G; Dyson PJ
    J Med Chem; 2005 Jun; 48(12):4161-71. PubMed ID: 15943488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding Kinetics of Ruthenium Pyrithione Chemotherapeutic Candidates to Human Serum Proteins Studied by HPLC-ICP-MS.
    Marković K; Milačič R; Marković S; Kladnik J; Turel I; Ščančar J
    Molecules; 2020 Mar; 25(7):. PubMed ID: 32225069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gold(I) complexes with alkylated PTA (1,3,5-triaza-7-phosphaadamantane) phosphanes as anticancer metallodrugs.
    García-Moreno E; Gascón S; Atrián-Blasco E; Rodriguez-Yoldi MJ; Cerrada E; Laguna M
    Eur J Med Chem; 2014 May; 79():164-72. PubMed ID: 24732792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.